Neomag (magnesium 97mg (4mmol)) chewable tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Magnesium glycerophosphate

Available from:

magnesium 97mg (4mmol)) chewable tablets (Neoceuticals Ltd

INN (International Name):

Magnesium glycerophosphate

Dosage:

97.2mg

Pharmaceutical form:

Chewable tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 09050103; GTIN: 5060256720058

Authorization date:

2022-01-09

Patient Information leaflet

PACI(AGE
TEAFIIIi
INFORMAflON
FORTHE
USER
NEOMAC
4
mmol
chewable
tablets
Magnesium
glycerophosphate
.
Keep
this
leaftet. You
may need to read
it
again.
.
lf
you
ha\re
any
fuilher
questions,
askyourdoc'tor,
pharmacist
or nurse.
.
This medicine has been
prescribed
for
you
only. Do not
pass
it
on to
others.
It
may
harm them,
even
if
their signs ot
illness
are th€ sama as
yorjrs.
.
lf
you get
any side
efiec.ts,
talk lo
your
dodor,
pharmacist
or nutEe.
This
indudes
any
possible
sids
efierts
not listed
in
this leaflet
grallwng
mla
Erorclne
foryou,
because
il contains
ln
this
leafre*:
You must wait
3-4
hours
between
taking
NEOMAG
3.
Howto
take NEOMAG
4.
Possible side
effeas
5.
Howto
store NEOMAG
6.
Further
in
ormation
NEOMAG
contains
magnesium
in
the torm of
magnesium
glycerophosphate.
Magnesium
is
an
essential
mineralwhich
is
important in many
activities
within
the body, especially nerve
and
muscle function.
NEOMAG
is
given
to
you
to supplement
magnesium
levels
when
the
level
o,
magnesium
in
your
body
is
too
low.
.
Amlnoqulnolineg
medicines used to treat malafia
.
Quinidine and
quinidine
derivatives,
medicines
used
to
treat heart rhythm
problems
.
Nitlo
urantoin,
Nitroxoline,
antibioticsto
treat
infe6tions
.
Penlclllamlne,
a medicine used to treat severe
rheumatoid
arthritis and used
in
Wilson's
disease
.
hon,
a medicine used to treat
anaemia
.
Bisphosphonaies,
mdicines
used
to
treat
osteoporosis,
sucfi as alendronate and
risedronate
.
Efirombopag,
a medicine used to
conect
bleeding
deficiency.
The following medicines
may cause
magneeium
2.
Beforeyou
Do
notkke
Neomag:
.
if
you
areallergictomagrEsium
g[rcerophowhate
or any of
the other
ingredients
of this
medklrp
(listed
in
sectbn 6)
.
if
you
have
phenylketonuria
(se'lrportant
intormation
abqrt
one
of
lhe ingredienH
below)
.
ii
you
have hyperphosphataemia
(high
levels
of
plrosphate
in
ydrr
bbd)
.
ityouhavekidneydisease
Vyamings
and
pt€cautiong
your
daily dose of
NEOMAG.
.
Aminoglycosides,
antibiolics used to
treat
infections,
sucfi as
gentamicin,
streptomycin
and
ne

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Neomag 4mmol chewable tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains magnesium glycerophosphate equivalent to
4 mmol
(97.2 mg) of magnesium.
Excipient(s) with known effect
Each tablet contains 10 mg aspartame.
For a full list of excipients, see Section 6.1.
3
PHARMACEUTICAL FORM
Chewable tablet
A white, round, flat tablet, cross-scored on one face. The score line
is only to
facilitate breaking for ease of swallowing and not to divide into
equal doses.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Neomag 4mmol Chewable Tablets are indicated as oral magnesium
supplements for
the treatment of patients with chronic magnesium loss or
hypomagnesaemia as
diagnosed by a doctor.
Neomag 4mmol Chewable Tablets are also indicated for adult patients
with
hypomagnesaemia due to the concomitant administration of loop and
thiazide
diuretics or other drugs which cause hypomagnesaemia.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_POSOLOGY _
Patients with severe, symptomatic hypomagnesaemia should receive
intravenous magnesium repletion for acute recovery of magnesium levels
prior
to receiving Neomag.
It is recommended that serum magnesium levels should be monitored at
regular
intervals (e.g. every 3-6 months), particularly in children and in
patients with renal
impairment.
ADULTS (> 18 YEARS): The dosage regimen should be adjusted according
to the serum
total magnesium level of the individual patient. Starting doses for
adult patients are
recommended as 4-8 mmol (1-2 tablets) administered 3 times a day. This
equates to
a total dose of 12 to 24 mmol per day taken in divided doses.
ELDERLY: No dose adjustment is necessary.
PAEDIATRIC POPULATION: Neomag tablets should only be used if the
benefits of
treatment outweigh any potential risks and under the supervision of
physicians
experienced in the management of children with hypomagnesaemia.
_Children: below 4 years_: Not recommended as there is insufficient
information
regarding the